Resources

• Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019
• An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, 2007 PUBMED.NCBI.NLM.NIH.GOV
• Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America, 2003
• An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy, 2006
• National Tuberculosis Coalition of America (NTCA) Guidelines for Respiratory Isolation and Restrictions to Reduce Transmission of Pulmonary Tuberculosis in Community Settings, 2024
• Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edition, 2022 Updates
• ATS/CDC/IDSA Guidelines for Treatment of Drug-Susceptible Tuberculosis, 2016

TB Infection

• Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
• Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection, CDC, 2018

Contact Investigation

• Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis, 2005

• Guidelines for Environmental Infection Control in Health-Care Facilities, CD 2003
• Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC, 2006

In an effort to characterize a snapshot of national TB trends in medical consultation inquiries, the following papers have been written through the collaborative efforts of CDC and the TB Centers of Excellence.

• Complexities of HIV-TB Care - A model for bringing TB expertise to HIV providers: Medical consultations to the CDC-funded Regional Tuberculosis Training and Medical Consultation Centers, 2013-2017 - PubMed (nih.gov)

• Controversies in Expert Advice for MDR TB - Multidrug-resistant tuberculosis care in the United States - PubMed (nih.gov)

• Pediatric TB - Pediatric tuberculosis consultations across 5 CDC regional tuberculosis training and medical consultation Centers - PubMed (nih.gov)

• Top questions, 2013-2017 - Tuberculosis in the United States: Medical Consultation Services Provided by 5 Tuberculosis Regional Training and Medical Consultation Centers, 2013-2017 - PubMed (nih.gov)

• Review of LTBI Questions/Advice - Challenges in LTBI care in the United States identified using a nationwide TB medical consultation database - PubMed (nih.gov)

TST/IGRA Interpreter - Estimates the risk of active tuberculosis for an individual with a tuberculin skin test reaction of ≥5mm, based on his/her clinical profile. It is intended for adults tested with standard tuberculin (5 TU PPDS, or 2 TU RT-23) and/or a commercial Interferon Gamma release assay (IGRA).this tool estimates the risk of active tuberculosis for an individual with a tuberculin skin test reaction of ≥5mm, based on his/her clinical profile. It is intended for adults tested with standard tuberculin (5 TU PPDS, or 2 TU RT-23) and/or a commercial Interferon Gamma release assay (IGRA).

TB Infectious Period Interactive Calendar - This tool uses patient symptom dates and treatment starts to generate a color-coded calendar that visually defines exposure windows. The tool assists with determining the infectious period during a TB contact investigation. It aids in identifying the period of time that an infected person may transmit TB disease to others, based on CDC’s 2005 guidelines. The tool helps identify priority contacts and determine if retesting is necessary based on the eight-week window. This tool should not be used as a substitute for professional judgment in determining infectious period. This tool should be used in partnership with a TB expert who can walk you through the dose counting process.


TB Treatment Dose Counting - This dose counting tool is used to accurately track the administration of daily TB medication doses throughout the treatment period using an online tool. This tool is for teaching purposes only and should not be used for patient treatment.  This tool should be used in partnership with a TB expert who can walk you through the dose counting process.

BPaL Monitoring (.docx)

MDR Weekly Assessment (.docx)

BPaL Regimen (.docx)